Anti-inflammatory mesenchymal stem cells (MSC2) attenuate symptoms of painful diabetic peripheral neuropathy

Stem Cells Translational Medicine

Volumn 1, Issue 7, 2012, Pages 557-565

  Waterman, Ruth S ^a   Morgenweck, Jenny ^b   Nossaman, Bobby D ^a   Scandurro, Anna E ^b   Scandurro, Sophia A ^b   Betancourt, Aline M ^b  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adult stem cells; Bone marrow stromal cells; Cellular therapy; Diabetes; Immunotherapy; Marrow stromal stem cells; Mesenchymal stem cells; Neuropathy

Indexed keywords

ALPHA CHEMOKINE; COLONY STIMULATING FACTOR 1; CXCL2 CHEMOKINE; CXCL9 CHEMOKINE; EOTAXIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 20; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9; KERATINOCYTE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; RANTES; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; AUTACOID; BIOLOGICAL MARKER; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BEHAVIOR; BLOOD SAMPLING; CONTROLLED STUDY; DIABETIC NEUROPATHY; HISTOLOGY; MALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PERIPHERAL NEUROPATHY; ALLOTRANSPLANTATION; ANIMAL; BLOOD; EXPERIMENTAL DIABETES MELLITUS; HUMAN; INFLAMMATION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY;

ANIMALS; BIOLOGICAL MARKERS; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84866725839     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2012-0025     Document Type: Article

References (64)

1. Argoff CE, Cole BE, Fishbain DA et al. Diabetic peripheral neuropathic pain: Clinical and quality-of-life issues. Mayo Clin Proc 2006;81: S3-S11.
2. Boulton AJ, Vinik AI, Arezzo JC et al. Diabetic neuropathies: A statement by the American Diabetes Association. Diabetes Care 2005; 28:956-962.
3. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004;5: 143-149.
4. Davies M, Brophy S, Williams R et al. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006;29:1518-1522.
5. Schmader KE. Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002; 18:350-354.
6. Van Acker K, Bouhassira D, De Bacquer D et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 2009;35:206-213.
7. Baron R, Tolle TR, Gockel U et al. A crosssectional cohort survey in 2100 patients with painful diabetic neuropathy and postherpetic neuralgia: Differences in demographic data and sensory symptoms. Pain 2009;146:34-40.
8. daCosta DiBonaventura M, Cappelleri JC, Joshi AV. A longitudinal assessment of painful diabetic peripheral neuropathy on health status, productivity, and health care utilization and cost. Pain Med 2011;12:118-126.
9. Vincent AM, Callaghan BC, Smith AL et al. Diabetic neuropathy: Cellular mechanisms as therapeutic targets. Nat Rev Neurol 2011;7: 573-583.
10. Dominiczak MH. Obesity, glucose intolerance and diabetes and their links to cardiovascular disease. Implications for laboratory medicine. Clin Chem Lab Med 2003;41:1266-1278.
11. Bailey CJ. Treating insulin resistance: Future prospects. Diab Vasc Dis Res 2007;4:20-31.
12. Kampoli AM, Tousoulis D, Briasoulis A et al. Potential pathogenic inflammatory mechanisms of endothelial dysfunction induced by type 2 diabetes mellitus. Curr Pharm Des 2011; 17:4147-4158.
13. Niehoff AG, van Haeften TW, Onland-Moret NC et al. C-reactive protein is independently associated with glucose but not with insulin resistance in healthy men. Diabetes Care 2007;30:1627-1629.
14. Sjöholm A, Nyström T. Endothelial inflammation in insulin resistance. Lancet 2005; 365:610-612.
15. Purwata TE. High TN. F-alpha plasma levels and macrophages iNOS and TNF-alpha expression as risk factors for painful diabetic neuropathy. J Pain Res 2011;4:169-175.
16. Uçeyler N, Rogausch JP, Toyka KV et al. Differential expression of cytokines in painful and painless neuropathies. Neurology 2007; 69:42-49.
17. Doupis J, Lyons TE, Wu S et al. Microvascular reactivity and inflammatory cytokines in painful and painless peripheral diabetic neuropathy. J Clin Endocrinol Metab 2009;94: 2157-2163.
18. Argoff CE, Backonja MM, Belgrade MJ et al. Consensus guidelines: Treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc 2006;81:S12-S25.
19. Barrett AM, Lucero MA, Le T et al. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: A review. Pain Med 2007;8(suppl 2):S50-S62.
20. Bunnell BA, Betancourt AM, Sullivan DE. New concepts on the immune modulation mediated by mesenchymal stem cells. Stem Cell Res Ther 2010;1:34.
21. Prockop DJ. Repair of tissues by adult stem/progenitor cells (MSCs): Controversies, myths, and changing paradigms. Mol Ther 2009;17:939-946.
22. Salem HK, Thiemermann C. Mesenchymal stromal cells: Current understanding and clinical status. STEM CELLS 2010;28:585-596.
23. Singer NG, Caplan AI. Mesenchymal stem cells: Mechanisms of inflammation. Annu Rev Pathol 2011;6:457-478.
24. von Bahr L, Batsis I, Moll G et al. Analysis of tissues following mesenchymal stromal cell therapy in humans indicate limited long-term engraftment and no ectopic tissue formation. STEM CELLS 2012 [Epub ahead of print].
25. Kim BJ, Jin HK, Bae JS. Bone marrow-derived mesenchymal stem cells improve the functioning of neurotrophic factors in a mouse model of diabetic neuropathy. Lab Anim Res 2011;27:171-176.
26. Shibata T, Naruse K, Kamiya H et al. Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats. Diabetes 2008;57:3099-3107.
27. Waterman RS, Tomchuck SL, Henkle SL et al. A new mesenchymal stem cell (MSC) paradigm: Polarization into a pro-inflammatory MSC1 or an immunosuppressive MSC2 phenotype. PLoS One 2010;5:e10088.
28. Betancourt AM, inventor; Administrators of the Tulane Educational Fund, assignee. Mesenchymal stem cells and related therapies. US patent pending 61/391 749. October 11, 2011.
29. Chaplan SR, Bach FW, Pogrel JW et al. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994;53:55-63.
30. Hargreaves K, Dubner R, Brown F et al. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988;32:7788.
31. Tomchuck SL, Zwezdaryk KJ, Coffelt SB et al. Toll-like receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. STEM CELLS 2008;26:99-107.
32. Betancourt AM, Waterman RS. The role of mesenchymal stem cells in the tumor microenvironment. In: Biswas S, ed. Tumor Microenvironment and Myelomonocytic Cells. In-Tech, 2012. Available at: http://www.intechopen.com/books/tumor-microenvironment-and-myelomonocytic-cells/the-role-of-mesenchymal-stem-cells-in-the-tumor-microenvironment. Accessed March 1, 2012.
33. Flodström M, Tyrberg B, Eizirik DL et al. Reduced sensitivity of inducible nitric oxide synthase-deficient mice to multiple low-dose streptozotocin-induced diabetes. Diabetes 1999;48:706-713.
34. Chopra K, Tiwari V, Arora V et al. Sesamol suppresses neuro-inflammatory cascade in experimental model of diabetic neuropathy. J Pain 2010;11:950-957.
35. Pabreja K, Dua K, Sharma S et al. Minocycline attenuates the development of diabetic neuropathic pain: Possible anti-inflammatory and anti-oxidant mechanisms. Eur J Pharmacol 2011;661:15-21.
36. Valsecchi AE, Franchi S, Panerai AE et al. The soy isoflavone genistein reverses oxidative and inflammatory state, neuropathic pain, neurotrophic and vasculature deficits in diabetes mouse model. Eur J Pharmacol 2011;650: 694-702.
37. Newman RE, Yoo D, LeRoux MA et al. Treatment of inflammatory diseases with mesenchymal stem cells. Inflamm Allergy Drug Targets 2009;8:110-123.
38. Waterman RS, Betancourt AM. Treating chronic pain with mesenchymal stem cells: A therapeutic approach worthy of continued investigation. J Stem Cell Res Ther 2011;S2:1-9.
39. Cameron NE, Tuck Z, McCabe L et al. Effect of the hydroxyl radical scavenger, dimethylthiourea, on peripheral nerve tissue perfusion, conduction velocity and nociception in experimental diabetes. Diabetologia 2001;44: 1161-1169.
40. Drel VR, Mashtalir N, Ilnytska O et al. The leptin-deficient (ob/ob) mouse: A new animal model of peripheral neuropathy of type 2 diabetes and obesity. Diabetes 2006;55:3335-3343.
41. Drel VR, Pacher P, Vareniuk I et al. Evaluation of the peroxynitrite decomposition catalyst Fe(III) tetra-mesitylporphyrin octasulfonate on peripheral neuropathy in a mouse model of type 1 diabetes. Int J Mol Med 2007; 20:783-792.
42. Ilnytska O, Lyzogubov VV, Stevens MJ et al. Poly(ADP-ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy. Diabetes 2006;55:1686-1694.
43. Stevens MJ, Li F, Drel VR et al. Nicotinamide reverses neurological and neurovascular deficits in streptozotocin diabetic rats. J Pharmacol Exp Ther 2007;320:458-464.
44. Obrosova IG. Diabetic painful and insensate neuropathy: Pathogenesis and potential treatments. Neurotherapeutics 2009;6:638-647.
45. Beiswenger KK, Calcutt NA, Mizisin AP. Epidermal nerve fiber quantification in the assessment of diabetic neuropathy. Acta Histochem 2008;110:351-362.
46. Herrmann DN, Griffin JW, Hauer P et al. Epidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies. Neurology 1999;53:1634-1640.
47. Muller KA, Ryals JM, Feldman EL et al. Abnormal muscle spindle innervation and large-fiber neuropathy in diabetic mice. Diabetes 2008;57:1693-1701.
48. Sinnreich M, Taylor BV, Dyck PJ. Diabetic neuropathies: Classification, clinical features, and pathophysiological basis. Neurologist 2005;11:63-79.
49. Bianco P. Back to the future: Moving beyond "mesenchymal stem cells." J Cell Biochem 2011;112:1713-1721.
50. Bianco P, Robey PG, Saggio I et al. "Mesenchymal" stem cells in human bone marrow (skeletal stem cells): A critical discussion of their nature, identity, and significance in incurable skeletal disease. Hum Gene Ther 2010;21: 1057-1066.
51. Bishnoi M, Bosgraaf CA, Abooj M et al. Streptozotocin-induced early thermal hyperalgesia is independent of glycemic state of rats: Role of transient receptor potential vanilloid 1(TRPV1) and inflammatory mediators. Mol Pain 2011;7:52.
52. Kumar A, Negi G, Sharma SS. JSH-23 targets nuclear factor-kappa B and reverses various deficits in experimental diabetic neuropathy: Effect on neuroinflammation and antioxidant defence. Diabetes Obes Metab 2011;13:750-758.
53. Luo L, Dai DZ, Cheng YS et al. Sildenafil improves diabetic vascular activity through suppressing endothelin receptor A, iNOS and NADPH oxidase which is comparable with the endothelin receptor antagonist CPU0213 in STZ-injected rats. J Pharm Pharmacol 2011;63: 943-951.
54. Silva DC, Freitas AL, Pessoa CD et al. Pectin from Passiflora edulis shows anti-inflammatory action as well as hypoglycemic and hypotriglyceridemic properties in diabetic rats. J Med Food 2011;14:1118-1126.
55. Fiorentino DF, Zlotnik A, Mosmann TR et al. IL-10 inhibits cytokine production by activated macrophages. J Immunol 1991;147: 3815-3822.
56. Soderquist RG, Milligan ED, Harrison JA et al. PEGylation of interleukin-10 for the mitigation of enhanced pain states. J Biomed Mater Res A 2010;93:1169-1179.
57. Cui JG, Holmin S, Mathiesen T et al. Possible role of inflammatory mediators in tactile hypersensitivity in rat models of mononeuropathy. Pain 2000;88:239-248.
58. Cruickshank AM, Fraser WD, Burns HJ et al. Response of serum interleukin-6 in patients undergoing elective surgery of varying severity. Clin Sci (Lond) 1990;79:161-165.
59. Holzheimer RG, Steinmetz W. Local and systemic concentrations of proand anti-inflammatory cytokines in human wounds. Eur J Med Res 2000;5:347-355.
60. Alexander GM, van Rijn MA, van Hilten JJ et al. Changes in cerebrospinal fluid levels of pro-inflammatory cytokines in CRPS. Pain 2005;116:213-219.
61. Watkins LR, Maier SF, Goehler LE. Immune activation: The role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Pain 1995;63: 289-302.
62. Yamakawa I, Kojima H, Terashima T et al. Inactivation of TNF-alpha ameliorates diabetic neuropathy in mice. Am J Physiol Endocrinol Metab 2011;301:E844-E852.
63. Xia P, Aiello LP, Ishii H et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 1996;98:2018-2026.
64. Samii A, Unger J, Lange W. Vascular endothelial growth factor expression in peripheral nerves and dorsal root ganglia in diabetic neuropathy in rats. Neurosci Lett 1999;262: 159-162.